by Maria Zannes | Jul 3, 2024 | Articles, News
bioAffinity Technologies News Update SAN ANTONIO, Texas (July 3, 2024) – We are pleased to share the latest updates from bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) as we continue to accelerate the commercialization of CyPath® Lung, our noninvasive diagnostic...
by Maria Zannes | Nov 8, 2023 | Articles, News
The latest move is a key step for an Alamo City company pursuing widespread adoption of its core technology. As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Nov. 6, 2023 San Antonio-based bioAffinity...
by Maria Zannes | Sep 27, 2023 | Articles, News
Sept. 26, 2023 As published in 360Dx By Greg Cima NEW YORK – bioAffinity has its eyes on expanding sales of its sputum-based lung cancer test nationwide through its recent acquisition of the pathology laboratory that had licensed and developed that technology into a...
by Maria Zannes | May 8, 2023 | Articles, News
bioAffinity Technologies CEO Maria Zannes says the company has made a key hire May 4, 2023 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. has made a key change in its...
by Maria Zannes | Mar 6, 2023 | Articles, News
MARCH 6, 2023 The Empowered Patient podcast host Karen Jagoda recently interviewed bioAffinity Technologies President and CEO Maria Zannes about the development of the CyPath® Lung test for the detection of early-stage lung cancer. Hear the podcast at...
by Maria Zannes | Feb 22, 2023 | Articles, News
FEBRUARY 22, 2023 bioAffinity Technologies President and CEO Maria Zannes recently joined host Seth Farbman on his podcast From Start-Up to Stock Exchange. Listen here https://lnkd.in/g-vkTfKv to learn more about the need for early screening for lung cancer when it is...
